Toward further simplification of elotuzumab therapy by subcutaneous administration

Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13.

¹ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. yshimura@koto.kpu-m.ac.jp.
² Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
³ Oncology Division, Bristol-Myers Squibb K.K, Shinjuku, Tokyo, 163-1327, Japan.
⁴ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. junkuro@koto.kpu-m.ac.jp.

No abstract available

Keywords: Elotuzumab; Multiple myeloma; Subcutaneous.

Publication types